Top

Open Access 27-09-2024 | IgA Nephropathy | Guidelines

IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

Authors: Marina Vivarelli, Susan Samuel, Rosanna Coppo, Jonathan Barratt, Melvin Bonilla-Felix, Dieter Haffner, Keisha Gibson, Mark Haas, Maher Ahmed Abdel-Hafez, Marta Adragna, Paul Brogan, Siah Kim, Isaac Liu, Zhi-Hong Liu, Mukta Mantan, Yuko Shima, Masaki Shimuzu, Qian Shen, Hernan Trimarchi, Deirdre Hahn, Elisabeth Hodson, Ken Pfister, Areefa Alladin, Olivia Boyer, Koichi Nakanishi, the International Pediatric Nephrology Association

Published in: Pediatric Nephrology

Abstract

IgA nephropathy and IgA vasculitis with nephritis, albeit rare, represent two relatively frequent glomerular conditions in childhood. Compared to adults, pediatric IgA nephropathy has a more acute presentation, most frequently with synpharyngitic macrohematuria and histologically with more intense inflammation and less intense chronic damage. Management of these conditions is controversial and supported by little high-quality evidence. The paucity of evidence is due to the disease heterogeneity, its inter-ethnic variability, and the difficulty of extrapolating data from adult studies due to the peculiarities of the condition in children. IgA vasculitis with nephritis is a kidney manifestation of a systemic disorder, typical of the pediatric age, in which both the diagnosis of kidney involvement and its management are poorly defined, and an interdisciplinary approach is crucial. Both conditions can have a profound and long-lasting impact on kidney function and the global health of affected children. The International Pediatric Nephrology Association has therefore convened a diverse international group of experts from different disciplines to provide guidance on the recommended management of these conditions in children and to establish common definitions and define priorities for future high-quality, evidence-based collaborative studies for the benefit of children.

Available only for authorised users

Wyatt RJ, Julian BA (2013) IgA Nephropathy. N Engl J Med 368:2402–2414. https://doi.org/10.1056/NEJMra1206793CrossRefPubMed

Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1–S276. https://doi.org/10.1016/j.kint.2021.05.021CrossRef

Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 38:435–442. https://doi.org/10.1016/j.semnephrol.2018.05.013CrossRefPubMed

Yeo SC, Cheung CK, Barratt J (2018) New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 33:763–777. https://doi.org/10.1007/s00467-017-3699-zCrossRefPubMed

Selewski DT, Ambruzs JM, Appel GB et al (2018) Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study. Kidney Int Rep 3:1373–1384. https://doi.org/10.1016/j.ekir.2018.07.021CrossRefPubMedPubMedCentral

Utsunomiya Y, Koda T, Kado T et al (2003) Incidence of pediatric IgA nephropathy. Pediatr Nephrol 18:511–515. https://doi.org/10.1007/s00467-003-1127-zCrossRefPubMed

Willey CJ, Coppo R, Schaefer F et al (2023) The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant 38:2340–2349. https://doi.org/10.1093/ndt/gfad082CrossRefPubMedPubMedCentral

Shibano T, Takagi N, Maekawa K et al (2016) Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol 20:111–117. https://doi.org/10.1007/s10157-015-1129-8CrossRefPubMed

Kamei K, Harada R, Hamada R et al (2016) Proteinuria during follow-up period and long-term renal survival of childhood IgA nephropathy. PLoS ONE 11:e0150885. https://doi.org/10.1371/journal.pone.0150885

10.

Coppo R, Robert T (2020) IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol 33:1219–1229. https://doi.org/10.1007/s40620-020-00725-0CrossRefPubMed

11.

Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677–686. https://doi.org/10.2215/CJN.07420716CrossRefPubMedPubMedCentral

12.

Barbour SJ, Espino-Hernandez G, Reich HN et al (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89:167–175. https://doi.org/10.1038/ki.2015.322CrossRefPubMed

13.

Yata N, Nakanishi K, Shima Y et al (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905–912. https://doi.org/10.1007/s00467-007-0726-5CrossRefPubMedPubMedCentral

14.

Pitcher D, Braddon F, Hendry B et al (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18:727–738. https://doi.org/10.2215/CJN.0000000000000135CrossRefPubMedPubMedCentral

15.

Yeo SC, Goh SM, Barratt J (2019) Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology 24:885–895. https://doi.org/10.1111/nep.13592CrossRefPubMed

16.

Kiryluk K, Li Y, Sanna-Cherchi S et al (2012) Geographic differences in genetic susceptibility to IgA nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8:e1002765. https://doi.org/10.1371/journal.pgen.1002765CrossRefPubMedPubMedCentral

17.

Su B, Jiang Y, Li Z et al (2024) Are children with IgA nephropathy different from adult patients? Pediatr Nephrol 39:2403–2412. https://doi.org/10.1007/s00467-024-06361-1CrossRefPubMedPubMedCentral

18.

Sestan M, Jelusic M (2023) Diagnostic and management strategies of iga vasculitis nephritis/Henoch-Schönlein purpura nephritis in pediatric patients: current perspectives. Pediatric Health Med Ther 14:89–98. https://doi.org/10.2147/PHMT.S379862CrossRefPubMedPubMedCentral

19.

Jauhola O, Ronkainen J, Koskimies O et al (2010) Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 95:871–876. https://doi.org/10.1136/adc.2009.167874CrossRefPubMed

20.

Peruzzi L, Coppo R (2021) IgA Vasculitis nephritis in children and adults: one or different entities? Pediatr Nephrol 36:2615–2625. https://doi.org/10.1007/s00467-020-04818-7CrossRefPubMed

21.

Ozen S, Marks SD, Brogan P et al (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. Rheumatology 58:1607–1616. https://doi.org/10.1093/rheumatology/kez041CrossRefPubMed

22.

Chen Y, Yang K, Marušic A et al (2017) A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med 166:128–132. https://doi.org/10.7326/M16-1565CrossRefPubMed

23.

Hahn D, Hodson EM, Craig JC (2023) Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst Rev 2023:CD005128. https://doi.org/10.1002/14651858.CD005128.pub4CrossRefPubMedCentral

24.

Steering Committee on Quality Improvement and Management (2004) Classifying recommendations for clinical practice guidelines. Pediatrics 114:874–877. https://doi.org/10.1542/peds.2004-1260CrossRef

25.

Trautmann A, Boyer O, Hodson E et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919. https://doi.org/10.1007/s00467-022-05739-3CrossRefPubMed

26.

Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571–590. https://doi.org/10.1016/S0031-3955(16)36251-4CrossRefPubMed

27.

Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843. https://doi.org/10.2215/CJN.01640309CrossRefPubMed

28.

Yoshikawa N, Ito H, Nakamura H (1988) IgA nephropathy in children from Japan. Clinical and Pathological Features. Child Nephrol Urol 9:191–199PubMed

29.

Southwest Pediatric Nephrology Study Group (1982) A multicenter study of IgA nephropathy in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 22:643–652. https://doi.org/10.1038/ki.1982.224CrossRef

30.

Rivera F, López-Gómez JM, Pérez-García R (2004) Clinicopathologic correlations of renal pathology in Spain. Kidney Int 66:898–904. https://doi.org/10.1111/j.1523-1755.2004.00833.xCrossRefPubMed

31.

Kashtan CE (2022) Genetic testing and glomerular hematuria—a nephrologist’s perspective. Am J Med Genet C Semin Med Genet 190:399–403. https://doi.org/10.1002/ajmg.c.31987CrossRefPubMedPubMedCentral

32.

Wang F, Zhao D, Ding J et al (2012) Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport’s syndrome. J Mol Diagn 14:586–593. https://doi.org/10.1016/j.jmoldx.2012.06.005CrossRefPubMed

33.

Nakanishi K, Yoshikawa N, Iijima K et al (1994) Immunohistochemical study of alpha 1–5 chains of type IV collagen in hereditary nephritis. Kidney Int 46:1413–1421. https://doi.org/10.1038/ki.1994.413CrossRefPubMed

34.

Trimarchi H, Barratt J, Cattran DC et al (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014–1021. https://doi.org/10.1016/j.kint.2017.02.003CrossRefPubMed

35.

Wu H, Fang X, Xia Z et al (2020) Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children—a retrospective 1243 cases analysis from single centre experience. J Nephrol 33:1263–1273. https://doi.org/10.1007/s40620-020-00767-4CrossRefPubMed

36.

Shima Y, Nakanishi K, Hama T et al (2012) Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 27:783–792. https://doi.org/10.1007/s00467-011-2061-0CrossRefPubMed

37.

Coppo R, Troyanov S, Camilla R et al (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927. https://doi.org/10.1038/ki.2010.43CrossRefPubMed

38.

Edstrom Halling S, Soderberg MP, Berg UB (2012) Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 27:715–722. https://doi.org/10.1093/ndt/gfr339CrossRefPubMed

39.

Le W, Zeng C-H, Liu Z et al (2012) Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol 13:158. https://doi.org/10.1186/1471-2369-13-158CrossRefPubMedPubMedCentral

40.

Haas M, Rahman MH, Cohn RA et al (2008) IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant 23:2537–2545. https://doi.org/10.1093/ndt/gfn014CrossRefPubMed

41.

Bergstein J, Leiser J, Andreoli S (2005) The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 159:353–355CrossRefPubMed

42.

Youn T, Trachtman H, Gauthier B (2006) Clinical spectrum of gross hematuria in pediatric patients. Clin Pediatr 45:135–141CrossRef

43.

Yuan X, Su Q, Wang H et al (2023) Genetic variants of the COL4A3, COL4A4, and COL4A5 genes contribute to thinned glomerular basement membrane lesions in sporadic IgA nephropathy patients. J Am Soc Nephrol 34:132–144. https://doi.org/10.1681/ASN.2021111447CrossRefPubMed

44.

Cambier A, Robert T, Hogan J et al (2021) Rare collagenous heterozygote variants in children with IgA nephropathy. Kidney Int Rep 6:1326–1335. https://doi.org/10.1016/j.ekir.2021.02.022CrossRefPubMedPubMedCentral

45.

Cambier A, Roy J-P, Dossier C et al (2024) IgA nephropathy in children with minimal proteinuria: to biopsy or not to biopsy? Pediatr Nephrol 39:781–787. https://doi.org/10.1007/s00467-023-06121-7CrossRefPubMed

46.

Hogg R (2022) An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy. Pediatr Nephrol 37:947–958. https://doi.org/10.1007/s00467-021-05092-xCrossRefPubMed

47.

Kincaid-Smith P, Bennett WM, Dowling JP, Ryan GB (1983) Acute renal failure and tubular necrosis associated with hematuria due to glomerulonephritis. Clin Nephrol 19:206–210PubMed

48.

Coppo R (2017) Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol 30:339–346. https://doi.org/10.1007/s40620-016-0360-zCrossRefPubMed

49.

Reich HN, Troyanov S, Scholey JW, Cattran DC (2007) Remission of proteinuria improves prognosis in IgA nephropathy. Clin J Am Soc Nephrol 18:3177–3183. https://doi.org/10.1681/ASN.2007050526CrossRef

50.

Suh J-S, Jang KM, Park YH et al (2020) Remission of proteinuria may protect against progression to chronic kidney disease in pediatric-onset IGA nephropathy. J Clin Med 9:1–17. https://doi.org/10.3390/jcm9072058CrossRef

51.

Inker LA, Lambers-Heerspink H, Tighiouart H et al (2021) Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis 78:340-349.e1. https://doi.org/10.1053/j.ajkd.2021.03.007CrossRefPubMedPubMedCentral

52.

Sevillano AM, Gutiérrez E, Yuste C et al (2017) Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 28:3089–3099. https://doi.org/10.1681/ASN.2017010108CrossRefPubMedPubMedCentral

53.

El Karoui K, Fervenza FC, De Vriese AS (2024) Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol 35:103–116. https://doi.org/10.1681/ASN.0000000000000242CrossRefPubMed

54.

Zand L, Fervenza FC, Coppo R (2023) Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients. Clin Kidney J 16:ii19–ii27. https://doi.org/10.1093/ckj/sfad232CrossRefPubMedPubMedCentral

55.

Shima Y, Nakanishi K, Hama T et al (2013) Spontaneous Remission in Children with IgA Nephropathy. Pediatr Nephrol 28:71–76. https://doi.org/10.1007/s00467-012-2294-6CrossRefPubMed

56.

Coppo R (2008) Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol 28:18–26. https://doi.org/10.1016/j.semnephrol.2007.10.003CrossRefPubMed

57.

Moriyama T, Tanaka K, Iwasaki C et al (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE 9:e91756. https://doi.org/10.1371/journal.pone.0091756

58.

Koyama A, Igarashi M, Kobayashi M (1997) Natural History and Risk Factors for Immunoglobulin A Nephropathy in Japan. Am J Kidney Dis 29:526–532. https://doi.org/10.1016/S0272-6386(97)90333-4CrossRefPubMed

59.

Worawichawong S, Plumworasawat S, Liwlompaisan W et al (2021) Distribution pattern of mesangial C4d deposits as predictor of kidney failure in IgA nephropathy. PLoS ONE 16:e0252638. https://doi.org/10.1371/journal.pone.0252638

60.

Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16:446–457. https://doi.org/10.1007/s004670100582CrossRefPubMed

61.

Calderon-Margalit R, Golan E, Twig G et al (2018) History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med 378:428–438. https://doi.org/10.1056/NEJMoa1700993CrossRefPubMed

62.

Stern-Zimmer M, Calderon-Margalit R, Skorecki K, Vivante A (2021) Childhood risk factors for adulthood chronic kidney disease. Pediatr Nephrol 36:1387–1396. https://doi.org/10.1007/s00467-020-04611-6CrossRefPubMed

63.

Yap HK, Teo S, Ng KH (2022) Pediatric nephrology: on-the-go, illustrated edn. World Scientific, SingaporeCrossRef

64.

Barbour SJ, Coppo R, Er L et al (2021) Updating the international IgA nephropathy prediction tool for use in children. Kidney Int 99:1439–1450. https://doi.org/10.1016/j.kint.2020.10.033CrossRefPubMed

65.

Lurbe E, Agabiti-Rosei E, Cruickshank JK et al (2016) 2016 European Society of Hypertension Guidelines for the Management of High Blood Pressure in Children and Adolescents. J Hypertens 34:1887–1920. https://doi.org/10.1097/HJH.0000000000001039CrossRefPubMed

66.

Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis 78:429–441. https://doi.org/10.1053/j.ajkd.2021.01.024CrossRefPubMed

67.

Coppo R, Peruzzi L, Amore A et al (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888. https://doi.org/10.1681/ASN.2006040347CrossRefPubMed

68.

Nakanishi K, Iijima K, Ishikura K et al (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845–849. https://doi.org/10.1007/s00467-008-1006-8CrossRefPubMed

69.

Shima Y, Nakanishi K, Sako M et al (2019) Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol 34:837–846. https://doi.org/10.1007/s00467-018-4099-8CrossRefPubMed

70.

Higa A, Shima Y, Hama T et al (2015) Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol 30:2121–2127. https://doi.org/10.1007/s00467-015-3176-5CrossRefPubMed

71.

Thompson A, Carroll K, Inker L et al (2019) Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14:469–481. https://doi.org/10.2215/CJN.08600718CrossRefPubMedPubMedCentral

72.

Coppo R (2021) Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol 36:491–496. https://doi.org/10.1007/s00467-020-04486-7CrossRefPubMed

73.

Shen W, Chen H, Chen H et al (2010) Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 5:1401–1409. https://doi.org/10.2215/CJN.01370210CrossRefPubMedPubMedCentral

74.

Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K et al (2014) The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin A nephropathy: a randomized controlled trial. J Ren Nutr 24:200–207. https://doi.org/10.1053/j.jrn.2014.01.016CrossRefPubMed

75.

Kataoka H, Ohara M, Shibui K et al (2012) Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 16:706–712. https://doi.org/10.1007/s10157-012-0613-7CrossRefPubMed

76.

Yin T, Chen Y, Tang L et al (2022) Relationship between modifiable lifestyle factors and chronic kidney disease: a bibliometric analysis of top-cited publications from 2011 to 2020. BMC Nephrol 23:120–135. https://doi.org/10.1186/s12882-022-02745-3CrossRefPubMedPubMedCentral

77.

Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883–887. https://doi.org/10.1016/s0140-6736(98)03563-6CrossRefPubMed

78.

Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163. https://doi.org/10.1097/01.ASN.0000103869.08096.4FCrossRefPubMed

79.

Manno C, Torres DD, Rossini M et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694–3701. https://doi.org/10.1093/ndt/gfp356CrossRefPubMed

80.

Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432–442. https://doi.org/10.1001/jama.2017.9362CrossRefPubMedPubMedCentral

81.

Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225–2236. https://doi.org/10.1056/NEJMoa1415463CrossRefPubMed

82.

Rauen T, Wied S, Fitzner C et al (2020) After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98:1044–1052. https://doi.org/10.1016/j.kint.2020.04.046CrossRefPubMed

83.

Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327:1888–1898. https://doi.org/10.1001/jama.2022.5368CrossRefPubMedPubMedCentral

84.

Niaudet P, Murcia I, Beaufils H et al (1993) Primary IgA nephropathies in children: prognosis and treatment. Adv Nephrol Necker Hosp 22:121–140PubMed

85.

Welch TR, Fryer C, Shely E et al (1992) Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121:474–477. https://doi.org/10.1016/S0022-3476(05)81808-6CrossRefPubMed

86.

Waldo FB, Wyatt RJ, Kelly DR et al (1993) Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 7:529–532CrossRefPubMed

87.

Hogg RJ, Lee J, Nardelli N et al (2006) Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1:467–474. https://doi.org/10.2215/CJN.01020905CrossRefPubMed

88.

Yoshikawa N, Ito H, Sakai T et al (1999) A controlled trial of combined therapy for newly diagnosed severe childhood iga nephropathy. J Am Soc Nephrol 10:101–109. https://doi.org/10.1681/ASN.V101101CrossRefPubMed

89.

Yoshikawa N, Honda M, Iijima K et al (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511–517. https://doi.org/10.2215/CJN.01120905CrossRefPubMed

90.

Kamei K, Nakanishi K, Ito S et al (2011) Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 6:1301–1307. https://doi.org/10.2215/CJN.08630910CrossRefPubMedPubMedCentral

91.

Shima Y, Nakanishi K, Kamei K et al (2011) Disappearance of glomerular IgA deposits in childhood iga nephropathy showing diffuse mesangial proliferation after 2 years of combination/ prednisolone therapy. Nephrol Dial Transplant 26:163–169. https://doi.org/10.1093/ndt/gfq387CrossRefPubMed

92.

Kawasaki Y, Maeda R, Kanno S et al (2017) Long-term follow up of pediatric immunoglobulin A nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. Pediatr Int 59:41–47. https://doi.org/10.1111/ped.13074CrossRefPubMed

93.

Cambier A, Rabant M, Peuchmaur M et al (2018) immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3:916–925. https://doi.org/10.1016/j.ekir.2018.03.013CrossRefPubMedPubMedCentral

94.

Ikezumi Y, Suzuki T, Imai N et al (2006) Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant 21:3466–3474CrossRefPubMed

95.

Coppo R (2019) Pediatric IgA nephropathy in Europe. Kidney Dis 5:182–188. https://doi.org/10.1159/000495751CrossRef

96.

Pozzi C, Andrulli S, Pani A et al (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783–1790. https://doi.org/10.1681/ASN.2010010117CrossRefPubMedPubMedCentral

97.

Ballardie FW, Roberts ISD (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148. https://doi.org/10.1681/ASN.V131142CrossRefPubMed

98.

Sarcina C, Tinelli C, Ferrario F et al (2016) Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11:973–981. https://doi.org/10.2215/CJN.02300215CrossRefPubMedPubMedCentral

99.

Yoshikawa N (2008) Treatment of childhood IgA nephropathy. Nippon Jinzo Gakkai Shi 50:468–472PubMed

100.

Shima Y, Nakanishi K, Kaku Y et al (2018) Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol 33:2103–2112. https://doi.org/10.1007/s00467-018-4011-6CrossRefPubMed

101.

Hou J-H, Le W-B, Chen N et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788–795. https://doi.org/10.1053/j.ajkd.2016.11.027CrossRefPubMed

102.

Hogg RJ, Bay RC, Jennette JC et al (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783–791. https://doi.org/10.1053/j.ajkd.2015.06.013CrossRefPubMed

103.

Hou FF, Xie D, Wang J et al (2023) Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 6:e2254054. https://doi.org/10.1001/jamanetworkopen.2022.54054CrossRefPubMed

104.

Han SY, Jung C-Y, Lee SH et al (2022) A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy. Kidney Res Clin Pract 41:452–461. https://doi.org/10.23876/j.krcp.21.146CrossRefPubMedPubMedCentral

105.

Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313. https://doi.org/10.1681/ASN.2016060640CrossRefPubMed

106.

Crayne CB, Eloseily E, Mannion ML et al (2018) Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J 16:71. https://doi.org/10.1186/s12969-018-0285-2CrossRefPubMedPubMedCentral

107.

Song Y-H, Cai G-Y, Xiao Y-F et al (2017) Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol 18:61–69. https://doi.org/10.1186/s12882-017-0467-zCrossRefPubMedPubMedCentral

108.

Liu L-J, Yang Y, Shi S-F et al (2019) Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 74:15–22. https://doi.org/10.1053/j.ajkd.2019.01.026CrossRefPubMed

109.

Selvaskandan H, Barratt J, Cheung CK (2024) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9:203–213. https://doi.org/10.1016/j.ekir.2023.11.026CrossRefPubMed

110.

US Food and Drug Administration (2021) FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. https://www.fda.gov/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease. Accessed 15 May 2024

111.

Rovin BH, Barratt J, Heerspink HJL et al (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3T trial. Lancet 402:2077–2090. https://doi.org/10.1016/S0140-6736(23)02302-4CrossRefPubMed

112.

Zhang H, Rizk DV, Perkovic V et al (2024) Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105:189–199. https://doi.org/10.1016/j.kint.2023.09.027CrossRefPubMed

113.

Williams J (2023) Omeros corporation provides update on interim analysis of ARTEMIS-IGAN phase 3 trial of narsoplimab in IgA nephropathy. https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-provides-update-interim-analysis-artemis-igan. Accessed 15 May 2024

114.

Caster DJ, Lafayette RA (2024) The treatment of primary IgA nephropathy: change, change, change. Am J Kidney Dis 83:229–240. https://doi.org/10.1053/j.ajkd.2023.08.007CrossRefPubMed

115.

Li X-H, Huang X-P, Pan L et al (2016) Vitamin D deficiency may predict a poorer outcome of IgA nephropathy. BMC Nephrol 17:164. https://doi.org/10.1186/s12882-016-0378-4CrossRefPubMedPubMedCentral

116.

Xiaowei L, Bo W, Li L, Peng Z (2020) Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int Urol Nephrol 52:129–136. https://doi.org/10.1007/s11255-019-02329-5CrossRefPubMed

117.

Deng J, Zheng X, Xie H, Chen L (2017) Calcitriol in the treatment of IgA nephropathy with non-nephrotic range proteinuria: a meta-analysis of randomized controlled trials. Clin Nephrol 87:21–27. https://doi.org/10.5414/CN108915CrossRefPubMed

118.

Liu L-J, Lv J-C, Shi S-F et al (2012) Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 59:67–74. https://doi.org/10.1053/j.ajkd.2011.09.014CrossRefPubMed

119.

Zan J, Ma J, Man Q et al (2022) Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis. Kidney Int Rep 7:1435–1436. https://doi.org/10.1016/j.ekir.2022.03.025CrossRefPubMedPubMedCentral

120.

Hanna C, Hernandez LPH, Bu L et al (2021) IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 100:705–706. https://doi.org/10.1016/j.kint.2021.06.032CrossRefPubMedPubMedCentral

121.

Ma Y, Xu G (2022) New-onset IgA nephropathy following COVID-19 vaccination. QJM 116:26–39. https://doi.org/10.1093/qjmed/hcac185CrossRefPubMedCentral

122.

Donadio JV, Bergstralh EJ, Offord KP et al (1994) a controlled trial of fish oil in IgA nephropathy. J Am Soc Nephrol 331:1194–1199. https://doi.org/10.1056/NEJM199411033311804CrossRef

123.

Donadio JVJ, Grande JP, Bergstralh EJ et al (1999) The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 10:1772–1777. https://doi.org/10.1681/ASN.V1081772CrossRefPubMed

124.

Donadio JV, Larson TS, Bergstralh EJ, Grande JP (2001) A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 12:791–799. https://doi.org/10.1681/ASN.V124791CrossRefPubMed

125.

Shen X-H, Liang S-S, Chen H-M et al (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28:441–449. https://doi.org/10.1007/s40620-014-0165-xCrossRefPubMed

126.

Shima Y, Nakanishi K, Sato M et al (2017) IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol 32:457–465. https://doi.org/10.1007/s00467-016-3502-6CrossRefPubMed

127.

Kang Z, Li Z, Duan C et al (2015) Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. Pediatr Nephrol 30:1121–1129. https://doi.org/10.1007/s00467-014-3041-yCrossRefPubMedPubMedCentral

128.

Pradhan SK, Sivaraj P, Das L, Swain A (2015) Spectrum of clinico-pathological profile and treatment response in children with nephrotic immunoglobulin A nephropathy. Saudi J Kidney Dis Transpl 26:708–711. https://doi.org/10.4103/1319-2442.160149CrossRefPubMed

129.

Yang D, He L, Peng X et al (2016) The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Renal Fail 38:242–248. https://doi.org/10.3109/0886022X.2015.1128251CrossRef

130.

Suzuki T, Yamamoto T, Ohura M et al (2004) Clinicopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/day. Clin Exp Nephrol 8:243–249. https://doi.org/10.1007/s10157-004-0299-6CrossRefPubMed

131.

Shima Y, Mukaiyama H, Tanaka Y et al (2024) Factors Related To Recurrence Of Proteinuria In Childhood Iga Nephropathy. Pediatr Nephrol 39:463–471. https://doi.org/10.1007/s00467-023-06116-4CrossRefPubMed

132.

Haas M (1997) Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 29:829–842. https://doi.org/10.1016/S0272-6386(97)90456-XCrossRefPubMed

133.

Gutierrez E, Rojas-Rivera J, Praga M et al (2012) Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23:1753–1760. https://doi.org/10.1681/ASN.2012010063CrossRefPubMedPubMedCentral

134.

Antonucci L, Fuiano L, Gargiulo A et al (2024) Childhood-onset IgA nephropathy: is long-term recovery possible? Pediatr Nephrol 39:1837–1846. https://doi.org/10.1007/s00467-023-06259-4CrossRefPubMed

135.

Coppo R, Lofaro D, Camilla RR et al (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139–150. https://doi.org/10.1007/s00467-016-3469-3CrossRefPubMed

136.

D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196. https://doi.org/10.1016/j.semnephrol.2004.01.001CrossRefPubMed

137.

Cochat P, Fargue S, Mestrallet G et al (2009) Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 24:2097–2108. https://doi.org/10.1007/s00467-009-1137-6CrossRefPubMedPubMedCentral

138.

Moroni G, Belingheri M, Frontini G et al (2019) Immunoglobulin A nephropathy Recurrence after renal transplantation. Front Immunol 10:1332. https://doi.org/10.3389/fimmu.2019.01332CrossRefPubMedPubMedCentral

139.

Suzuki K, Honda K, Tanabe K et al (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63:2286–2294. https://doi.org/10.1046/j.1523-1755.63.6s.2.xCrossRefPubMed

140.

Gaber LW, Khan FN, Graviss EA et al (2020) Prevalence, characteristics, and outcomes of incidental IgA glomerular deposits in donor kidneys. Kidney Int Rep 5:1914–1924. https://doi.org/10.1016/j.ekir.2020.08.018CrossRefPubMedPubMedCentral

141.

Silva FG, Chander P, Pirani CL, Hardy MA (1982) Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33:241–246PubMed

142.

Odum J, Peh CA, Clarkson AR et al (1994) Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 9:309–312PubMed

143.

Berger J (1988) Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 12:371–372. https://doi.org/10.1016/s0272-6386(88)80027-1CrossRefPubMed

144.

Fisher NC, Nightingale PG, Gunson BK et al (1998) Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 66:59–66. https://doi.org/10.1097/00007890-199807150-00010CrossRefPubMed

145.

Bumgardner GL, Amend WC, Ascher NL, Vincenti FG (1998) Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 65:1053–1060CrossRefPubMed

146.

Choy BY, Chan TM, Lo SK et al (2003) Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 18:2399–2404. https://doi.org/10.1093/ndt/gfg373CrossRefPubMed

147.

Floege J (2004) Recurrent IgA nephropathy after renal transplantation. Semin Nephrol 24:287–291. https://doi.org/10.1016/j.semnephrol.2004.01.008CrossRefPubMed

148.

Ohmacht C, Kliem V, Burg M et al (1997) Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation 64:1493–1496. https://doi.org/10.1097/00007890-199711270-00024CrossRefPubMed

149.

Ponticelli C (2001) The activity of the division of nephrology and dialysis. Osp Magg 95:116–119

150.

Briganti EM, Russ GR, McNeil JJ et al (2002) Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347:103–109. https://doi.org/10.1056/NEJMoa013036CrossRefPubMed

151.

Clayton P, McDonald S, Chadban S (2011) Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 11:1645–1649. https://doi.org/10.1111/j.1600-6143.2011.03667.xCrossRefPubMed

152.

Leeaphorn N, Garg N, Khankin EV et al (2018) Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transpl Int 31:175–186. https://doi.org/10.1111/tri.13075CrossRefPubMed

153.

Di Vico MC, Messina M, Fop F et al (2018) Recurrent IgA nephropathy after renal transplantation and steroid withdrawal. Clin Transplant 32:e13207. https://doi.org/10.1111/ctr.13207CrossRefPubMed

154.

Andreoli SP, Bergstein JM (1989) Treatment of severe IgA nephropathy in children. Pediatr Nephrol 3:248–253. https://doi.org/10.1007/BF00858524CrossRefPubMed

155.

Eckardt K-U, Kasiske BL, Zeier MG (2009) Special issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J of Transplant 9:S1–S155. https://doi.org/10.1111/j.1600-6143.2009.02834.xCrossRef

156.

Oka K, Imai E, Moriyama T et al (2000) A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 15:689–695. https://doi.org/10.1093/ndt/15.5.689CrossRefPubMed

157.

Courtney AE, McNamee PT, Nelson WE, Maxwell AP (2006) Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 21:3550–3554. https://doi.org/10.1093/ndt/gfl506CrossRefPubMed

158.

Glassock RJ (2021) IgA nephropathy: “The Times They Are a-Changin.” Glomerular Dis 2:4–14. https://doi.org/10.1159/000515199CrossRefPubMedPubMedCentral

159.

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715CrossRefPubMed

160.

Hunder GG (1998) The use and misuse of classification and diagnostic criteria for complex diseases. Ann Intern Med 129:417–418. https://doi.org/10.7326/0003-4819-129-5-199809010-00013CrossRefPubMed

161.

Robson J, Grayson P, Ponte C et al (2022) 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis with Polyangiitis. Ann Rheum Dis 81:315–320. https://doi.org/10.1136/annrheumdis-2021-221795CrossRefPubMed

162.

Mills JA, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 Criteria for the Classification of Henoch-Schönlein Purpura. Arthritis Rheum 33:1114–1121. https://doi.org/10.1002/art.1780330809CrossRefPubMed

163.

Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood wegener granulomatosis and childhood takayasu arteritis: Ankara 2008. Part II: Final Classification Criteria. Ann Rheum Dis 69:798–806. https://doi.org/10.1136/ard.2009.116657CrossRefPubMed

164.

Linskey KR, Kroshinsky D, Mihm MC, Hoang MP (2012) Immunoglobulin-A–associated small-vessel vasculitis: a 10-year experience at the Massachusetts General Hospital. J Am Acad Dermatol 66:813–822. https://doi.org/10.1016/j.jaad.2011.06.012CrossRefPubMed

165.

Haas M, Jafri J, Bartosh SM et al (2000) ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 36:709–718. https://doi.org/10.1053/ajkd.2000.17615CrossRefPubMed

166.

Coppo R, Andrulli S, Amore A et al (2006) Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis 47:993–1003CrossRefPubMed

167.

Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 360:666–670. https://doi.org/10.1016/S0140-6736(02)09835-5CrossRefPubMed

168.

Koskela M, Ylinen E, Ukonmaanaho E-M et al (2017) The ISKDC classification and a new semiquantitative classification for predicting outcomes of Henoch-Schönlein purpura nephritis. Pediatr Nephrol 32:1201–1209. https://doi.org/10.1007/s00467-017-3608-5CrossRefPubMed

169.

Barbour SJ, Coppo R, Er L et al (2024) Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis. Clin J Am Soc Nephrol 19:438–451. https://doi.org/10.2215/CJN.0000000000000398CrossRefPubMed

170.

Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920. https://doi.org/10.1136/adc.2005.074641CrossRefPubMedPubMedCentral

171.

Kawasaki Y, Suzuki J, Sakai N et al (2003) Clinical and pathological features of children with Henoch-Schoenlein Purpura nephritis: risk factors associated with poor prognosis. Clin Nephrol 60:153–160CrossRefPubMed

172.

Edström Halling S, Söderberg MP, Berg UB (2009) Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis A single center experience. Pediatr Nephrol 24:91–97. https://doi.org/10.1007/s00467-008-0990-zCrossRefPubMed

173.

Goldstein AR, White RHR, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 339:280–282. https://doi.org/10.1016/0140-6736(92)91341-5CrossRefPubMed

174.

Counahan R, Winterborn MH, White RH et al (1977) Prognosis of Henoch-Schönlein nephritis in children. Br Med J 2:11–14. https://doi.org/10.1136/bmj.2.6078.11CrossRefPubMedPubMedCentral

175.

Dudley J, Smith G, Llewelyn-Edwards A et al (2013) Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schönlein purpura (HSP). Arch Dis Child 98:756–763. https://doi.org/10.1136/archdischild-2013-303642CrossRefPubMed

176.

Huber AM, King J, McLaine P et al (2004) A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein purpura [ISRCTN85109383]. BMC Med 2:7. https://doi.org/10.1186/1741-7015-2-7CrossRefPubMedPubMedCentral

177.

Ronkainen J, Ala-Houhala M, Autio-Harmainen H et al (2006) Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 21:1266–1273. https://doi.org/10.1007/s00467-006-0163-xCrossRefPubMed

178.

Peratoner L, Longo F, Lepore L, Freschi P (1990) Prophylaxis and therapy of glomerulonephritis in the course of anaphylactoid purpura: the results of a polycentric clinical trial. Acta Paediatr 79:976–977. https://doi.org/10.1111/j.1651-2227.1990.tb11365.xCrossRef

179.

Yoshimoto M, Ito H, Shindo S, Yamashita F (1987) Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]. Pediatr Nephrol 1:C47

180.

Tian M, Liu C (2015) Heparin calcium treated Henoch-Schönlein purpura nephritis in children through inhibiting hyperfibrinolysis. Ren Fail 37:1100–1104. https://doi.org/10.3109/0886022X.2015.1061668CrossRefPubMed

181.

Wu S-H, Liao P-Y, Chen X-Q et al (2014) Add-on therapy with montelukast in the treatment of Henoch-Schönlein purpura. Pediatr Int 56:315–322. https://doi.org/10.1111/ped.12271CrossRefPubMed

182.

Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of schönlein-henoch purpura nephritis. Pediatr Nephrol 12:238–243. https://doi.org/10.1007/s004670050446CrossRefPubMed

183.

Tarshish P, Bernstein J, Edelmann CM (2004) Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56. https://doi.org/10.1007/s00467-003-1315-xCrossRefPubMed

184.

Jauhola O, Ronkainen J, Autio-Harmainen H et al (2011) Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol 26:2159–2166. https://doi.org/10.1007/s00467-011-1919-5CrossRefPubMed

185.

Zhang H, Li X, Xu H et al (2021) Effect and safety evaluation of tacrolimus and tripterygium glycosides combined therapy in treatment of Henoch-Schönlein purpura nephritis. Int J Urol 28:1157–1163. https://doi.org/10.1111/iju.14665CrossRefPubMed

186.

Ninchoji T, Kaito H, Nozu K et al (2011) Treatment strategies for Henoch-Schonlein purpura nephritis by histological and clinical severity. Pediatr Nephrol 26:563–569. https://doi.org/10.1007/s00467-010-1741-5CrossRefPubMed

187.

Nagai S, Horinouchi T, Ninchoji T et al (2023) Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis. Pediatr Nephrol 38:4023–4031. https://doi.org/10.1007/s00467-023-06052-3CrossRefPubMed

188.

Lu Z, Song J, Mao J et al (2017) Evaluation of mycophenolate mofetil and low-dose steroid combined therapy in moderately severe Henoch-Schönlein purpura nephritis. Med Sci Monit 23:2333–2339. https://doi.org/10.12659/msm.904206CrossRefPubMedPubMedCentral

189.

Hackl A, Becker JU, Korner LM et al (2018) Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schonlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 33:619–629. https://doi.org/10.1007/s00467-017-3846-6CrossRefPubMed

190.

Kallash M, Vogt BA, Zeid A et al (2022) The scope of treatment of pediatric IgA vasculitis nephritis and its outcome: a pediatric nephrology research consortium study. Pediatr Nephrol 37:2687–2697. https://doi.org/10.1007/s00467-022-05496-3CrossRefPubMed

191.

Kurt-Şükür ED, Tullus K (2022) Response to: timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA vasculitis nephritis. Pediatr Nephrol 37:915–915. https://doi.org/10.1007/s00467-021-05416-xCrossRefPubMed

192.

Du Y, Hou L, Zhao C et al (2012) Treatment of children with Henoch-Schonlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol 27:765–771. https://doi.org/10.1007/s00467-011-2057-9CrossRefPubMed

193.

Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V et al (1997) Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 40:859–864. https://doi.org/10.1002/art.1780400513CrossRefPubMed

194.

Shin JI, Park JM, Shin YH et al (2006) Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura. Scand J Rheumatol 35:56–60. https://doi.org/10.1080/03009740510026841CrossRefPubMed

195.

Gökçe Ş, Kurugöl Z, Koturoğlu G, Aslan A (2020) Predictive role of laboratory markers and clinical features for recurrent Henoch-Schönlein purpura in childhood: a study from Turkey. Mod Rheumatol 30:1047–1052. https://doi.org/10.1080/14397595.2019.1690966CrossRefPubMed

196.

Rigante D, Candelli M, Federico G et al (2005) Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura. Rheumatol Int 25:45–48. https://doi.org/10.1007/s00296-004-0452-2CrossRefPubMed

197.

Ekinci RMK, Balci S, Melek E et al (2020) Clinical manifestations and outcomes of 420 children with Henoch Schönlein purpura from a single referral center from Turkey: a three-year experience. Mod Rheumatol 30:1039–1046. https://doi.org/10.1080/14397595.2019.1687074CrossRefPubMed

198.

Calvo-Río V, Hernández JL, Ortiz-Sanjuán F et al (2016) Relapses in patients with Henoch-Schönlein purpura: analysis of 417 patients from a single center. Medicine 95:e4217. https://doi.org/10.1097/MD.0000000000004217CrossRefPubMedPubMedCentral

199.

Karadağ ŞG, Tanatar A, Sönmez HE et al (2019) The clinical spectrum of Henoch-Schönlein purpura in children: a single-center study. Clin Rheumatol 38:1707–1714. https://doi.org/10.1007/s10067-019-04460-1CrossRefPubMed

200.

Lei W-T, Tsai P-L, Chu S-H et al (2018) Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol Online J 16:25. https://doi.org/10.1186/s12969-018-0247-8CrossRefPubMedPubMedCentral

201.

Dolezalova P, Price-Kuehne FE, Özen S et al (2013) Disease activity assessment in childhood vasculitis: development and preliminary validation of the paediatric vasculitis activity score (PVAS). Ann Rheum Dis 72:1628–1633. https://doi.org/10.1136/annrheumdis-2012-202111CrossRefPubMed

202.

Pirojsakul K, Tangnararatchakit K, Chalermsanyakorn P, Tapaneya-Olarn W (2012) Clinical outcome of children with Henoch-Schönlein purpura nephritis. J Med Assoc Thai 95:878–883PubMed

203.

Coppo R, Mazzucco G, Cagnoli L et al (1997) Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein Purpura. Nephrol Dial Transplant 12:2277–2283. https://doi.org/10.1093/ndt/12.11.2277CrossRefPubMed

204.

Delbet J-D, Geslain G, Auger M et al (2020) Histological prognostic factors in children with Henoch-Schönlein purpura nephritis. Pediatr Nephrol 35:313–320. https://doi.org/10.1007/s00467-019-04363-yCrossRefPubMed

Title: IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis
Authors: Marina Vivarelli
Susan Samuel
Rosanna Coppo
Jonathan Barratt
Melvin Bonilla-Felix
Dieter Haffner
Keisha Gibson
Mark Haas
Maher Ahmed Abdel-Hafez
Marta Adragna
Paul Brogan
Siah Kim
Isaac Liu
Zhi-Hong Liu
Mukta Mantan
Yuko Shima
Masaki Shimuzu
Qian Shen
Hernan Trimarchi
Deirdre Hahn
Elisabeth Hodson
Ken Pfister
Areefa Alladin
Olivia Boyer
Koichi Nakanishi
the International Pediatric Nephrology Association
Publication date: 27-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: IgA Nephropathy
IgA Vasculitis
IgA Vasculitis
Hematuria
Glucocorticoid
Published in: Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-024-06502-6

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

Abstract

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Please log in to get access to this content